

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Proposed Health Technology Appraisal

Review of TA No. 101; docetaxel for the treatment of hormone refractory prostate cancer

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> • Sanofi-aventis (taxotere) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Afiya Trust • Age Concern England • Black Health Agency • Bob Champion Cancer Trust • CANCERactive • Cancerbackup • Cancer Black Care • Cancer Equality • Cancer Voices • Chinese National Healthy Living Centre • Confederation of Indian Organisations • Counsel and Care • Equalities National Council • Everyman • Helen Rollason Heal Cancer Charity • Help the Aged • Macmillan Cancer Support • Maggie's Centres • Marie Curie Cancer Care • Muslim Council of Great Britain • Muslim Health Network • National Cancer Alliance • Orchid • PCaSO – Prostate Cancer Network • Prostate Cancer Charity • Prostate Help Association 	<p><u>General</u></p> <ul style="list-style-type: none"> • Age Concern Cymru • Board of Community Health Councils in Wales • British National Formulary • Cancer Care Cymru • Department of Health, Social Services and Public Safety for Northern Ireland • Medicines and Healthcare Products Regulatory Agency • National Association for Primary Care • National Public Health Service for Wales • NHS Alliance • NHS Confederation • NHS Purchasing and Supply Agency • NHS Quality Improvement Scotland • Scottish Medicines Consortium <p><u>Comparator manufacturers</u></p> <ul style="list-style-type: none"> • Baxter Oncology (mitoxantrone) • Dabur Pharma (mitoxantrone) • Hospira (mitoxantrone) • Pfizer (estramustine) • Teva Pharmaceuticals (mitoxantrone) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Institute of Cancer Research • MRC Clinical Trials Unit • National Cancer Research Institute • National Cancer Research Network • National Institute of Health Research

National Institute for Health and Clinical Excellence
 Matrix of consultees and commentators for the review proposal of NICE Technology Appraisal
 Guidance no. 101; docetaxel for the treatment of hormone refractory prostate cancer

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • PSA – Prostate Cancer Support Association • Specialised Healthcare Alliance • South Asian Health Foundation • Sue Ryder Care • Tenovus Cancer Information Centre <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Cancer Physicians • British Association for Services to the Elderly • British Association of Urological Nurses • British Association of Urological Surgeons • British Geriatrics Society • British Oncological Association • British Prostate Group • British Psychosocial Oncology Society • British Uro-oncology Group • Cancer Networks Pharmacists Forum • Cancer Research UK • Prostate Brachytherapy Advisory Group • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians, Medical Oncology Joint Special Committee • Royal College of Radiologists • Royal Society of Medicine – Intellectual Disabilities Forum • Society and College of Radiographers • United Kingdom Clinical Pharmacy Association • United Kingdom Oncology Nursing Society <p><u>Others</u></p>	<ul style="list-style-type: none"> • Ovarian & Prostate Cancer Research Trust • Policy Research Institute on Ageing and Ethnicity • Pro-Cancer Research Foundation • Prostate Cancer Research Foundation • Prostate UK • Radiological Research Trust • Research Institute of the Care of Older People <p><u>Assessment Group</u></p> <ul style="list-style-type: none"> • Assessment Group tbc • National Institute for Health Research Health Technology Assessment Programme <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> • National Collaborating Centre for Cancer <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • tbc

National Institute for Health and Clinical Excellence
 Matrix of consultees and commentators for the review proposal of NICE Technology Appraisal
 Guidance no. 101; docetaxel for the treatment of hormone refractory prostate cancer

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Bath and North East Somerset PCT • Department of Health • Pembrokeshire LHB • Welsh Assembly Government 	

NICE is committed to promoting equality and eliminating unlawful discrimination. Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the

National Institute for Health and Clinical Excellence
 Matrix of consultees and commentators for the review proposal of NICE Technology Appraisal Guidance no. 101; docetaxel for the treatment of hormone refractory prostate cancer

Welsh Assembly Government and relevant NHS organisations in England.

Consultees can participate in the consultation on the draft scope, the Assessment Report and the Appraisal Consultation Document, they are invited to prepare a submission dossier and all non-manufacturers/sponsors consultee organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee. All consultees are given the opportunity to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare a submission dossier, and that receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*).

All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

Assessment team

An independent academic group (commissioned by the NHS Research and Development Health Technology Assessment Programme [HTA Programme] to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies) based on a systematic review of the literature and a review of manufacturer and sponsor submission to the Institute).